HP is partnering with the US Centers for Disease Control (CDC) on a trial programme aimed at tackling super bugs and antibiotic resistance, by printing and testing drugs in a bid to catch and stem the spread of antimicrobial resistant strains. The project will see the creation of an automated manufacturing system that can produce up to 100 million doses per year of various antibiotics.
HP is partnering with the US Centers for Disease Control (CDC) on a trial programme aimed at tackling super bugs and antibiotic resistance, by printing and testing drugs in a bid to catch and stem the spread of antimicrobial resistant strains. The pilot scheme is using HP’s D300e Digital Dispenser BioPrinter technology, which is able to dispense drugs in any combination or quantity for the purposes of research.